Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mylotarg, Event-Free Survival Endpoint Both Get FDA Panel Endorsement

Executive Summary

Oncologic Drugs Advisory Committee votes 6-1 that benefits of Pfizer's Mylotarg outweigh risks, positioning drug for return to market after being withdrawn in 2010; vote could also open door for future acute myeloid leukemia products to use event-free survival as endpoint.

You may also be interested in...



Daiichi's AML Drug Quizartinib Heads To ODAC With Host Of Efficacy, Safety Issues

US FDA's Oncologic Drugs Advisory Committee will examine Daicchi Sankyo's acute myeloid lekemia drug quizartinib in the second of two half-day panels for the sponsor.

Oncology Endpoint Guidance: US FDA Reaffirms Support For EFS, MRD In Update

Update of 2007 guidance includes discussion on use of newer endpoints and clarifies that oncology endpoints can serve different purposes.

More Good News For AML As Pfizer And AbbVie/Roche Drugs Get FDA Okay

The options for AML are on the rise after no drugs for decades and the green lights for Daurismo and Venclexta mean that seven therapies for the disease have now been approved by the FDA since 2017.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS121084

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel